INS and type 2 diabetes mellitus: Studies have shown that tamoxifen use can reduce insulin sensitivity and may even promote apoptosis of pancreatic β‐cells, contributing to an increased risk of type 2 diabetes mellitus and increased visceral adipose tissue, as reflected by elevated sagittal abdominal diameter (SAD) [18, 19].